Jump to section
To bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
-35% employee growth in 12 months
Invitae is a medical genetics company that is focused on bringing comprehensive genetic information into mainstream medicine, to improve healthcare for all people at any stage of their life. Its platform is made for providers and patients, with the ability to customize genetic tests in just a few clicks, and flexible pricing that ensures the service is widely accessible.
Despite being lauded for its low selling prices and high testing volume - which makes clinical-grade genetic testing available to the masses - Invitae has received criticism for the way it has been managed. This resulted in a strategic restructuring of the company in 2022, which deprioritised the company's focus on growth, so it could focus on becoming a more sustainable business. In 2024, it listed itself as bankrupt and through a sale, was purchased by Labcorp.
Despite this tumult, Invitae's new home at Labcorp means the company can still extend its platform. Further development of Invitae will be fueled by a range of investments in the form of convertible debt due in 2028 and share exchanges.
Steph
Company Specialist at Welcome to the Jungle
Oct 2014
$120m
SERIES F
Dec 2013
$40m
SERIES E
This company has top investors
Kenneth Knight
(CEO, not founder)Previously worked at Amazon as Vice President, leading Middle Mile operations. Initially served as COO at Invitae, becoming CEO in 2022.